View Future GrowthEMS-CHEMIE HOLDING 過去の業績この会社の最新の決算報告書はまだ処理中です過去 基準チェック /56EMS-CHEMIE HOLDINGの収益は年間平均-2.8%の割合で減少していますが、 Chemicals業界の収益は年間 減少しています。収益は年間1.2% 1.4%割合で 減少しています。 EMS-CHEMIE HOLDINGの自己資本利益率は25.3%であり、純利益率は23.7%です。主要情報-2.77%収益成長率-2.77%EPS成長率Chemicals 業界の成長23.20%収益成長率-1.36%株主資本利益率25.33%ネット・マージン23.69%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €845, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Chemicals industry in Italy. Total returns to shareholders of 28% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €656 per share.お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.Buy Or Sell Opportunity • Jun 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €770. The fair value is estimated to be €637, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings are also forecast to grow by 5.2% per annum over the same time period.New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Jun 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €775. The fair value is estimated to be €645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 4.7% per annum over the same time period.Buy Or Sell Opportunity • May 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €765. The fair value is estimated to be €633, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.6% per annum. Earnings are also forecast to grow by 4.5% per annum over the same time period.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Feb 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €690. The fair value is estimated to be €569, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last 3 years. Earnings per share has declined by 3.6%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 4.9% per annum over the same time period.Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026Board Change • Feb 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026Board Change • Sep 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Aug 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.収支内訳EMS-CHEMIE HOLDING の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BIT:1EMSN 収益、費用、利益 ( )CHF Millions日付収益収益G+A経費研究開発費31 Dec 251,969467254030 Sep 251,996464257030 Jun 252,024462260031 Mar 252,057461260031 Dec 242,091461260030 Sep 242,104461251030 Jun 242,117462243031 Mar 242,165460243031 Dec 232,213458243030 Sep 232,294475247030 Jun 232,374493251031 Mar 232,425512251031 Dec 222,475532251030 Sep 222,438545245030 Jun 222,401557239031 Mar 222,342554239031 Dec 212,283550239030 Sep 212,218536228030 Jun 212,154521217031 Mar 211,994478217031 Dec 201,833434217030 Sep 201,867444230030 Jun 201,900453244031 Mar 202,055490244031 Dec 192,209527244030 Sep 192,257527249030 Jun 192,305527254031 Mar 192,327523254031 Dec 182,350520254030 Sep 182,330517244030 Jun 182,310515234031 Mar 182,243498234031 Dec 172,177482234030 Sep 172,126471236030 Jun 172,076461238031 Mar 172,044455238031 Dec 162,012449238030 Sep 161,987428235030 Jun 161,962407232031 Mar 161,947392232031 Dec 151,932376232030 Sep 151,9443602440質の高い収益: 1EMSNは 高品質の収益 を持っています。利益率の向上: 1EMSNの現在の純利益率 (23.7%)は、昨年(22%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 1EMSNの収益は過去 5 年間で年間2.8%減少しました。成長の加速: 1EMSNの過去 1 年間の収益成長率 ( 1.2% ) は、5 年間の平均 ( 年間-2.8%を上回っています。収益対業界: 1EMSNの過去 1 年間の収益成長率 ( 1.2% ) はChemicals業界0.1%を上回りました。株主資本利益率高いROE: 1EMSNの 自己資本利益率 ( 25.3% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/28 09:25終値2026/07/28 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EMS-CHEMIE HOLDING AG 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14 アナリスト機関Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchAdrien TamagnoBerenberg11 その他のアナリストを表示
Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.
お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026
お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €845, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 13x in the Chemicals industry in Italy. Total returns to shareholders of 28% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €656 per share.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 08, 2026, at 10:30 W. Europe Standard Time.
Buy Or Sell Opportunity • Jun 30Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €770. The fair value is estimated to be €637, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings are also forecast to grow by 5.2% per annum over the same time period.
New Risk • Jun 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Jun 09Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €775. The fair value is estimated to be €645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are also forecast to grow by 4.7% per annum over the same time period.
Buy Or Sell Opportunity • May 22Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 11% to €765. The fair value is estimated to be €633, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.7% over the last 3 years. Earnings per share has declined by 3.7%. For the next 3 years, revenue is forecast to grow by 2.6% per annum. Earnings are also forecast to grow by 4.5% per annum over the same time period.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Feb 10Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 15% to €690. The fair value is estimated to be €569, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 7.8% over the last 3 years. Earnings per share has declined by 3.6%. For the next 3 years, revenue is forecast to grow by 3.4% per annum. Earnings are also forecast to grow by 4.9% per annum over the same time period.
Reported Earnings • Feb 08Full year 2025 earnings released: EPS: CHF19.97 (vs CHF19.70 in FY 2024)Full year 2025 results: EPS: CHF19.97 (up from CHF19.70 in FY 2024). Revenue: CHF1.95b (down 6.7% from FY 2024). Net income: CHF467.0m (up 1.3% from FY 2024). Profit margin: 24% (up from 22% in FY 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Chemicals industry in Italy.
お知らせ • Feb 05+ 1 more updateEMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Final Results on Jul 10, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 final results on Jul 10, 2026
Board Change • Feb 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 06EMS-CHEMIE HOLDING AG to Report Fiscal Year 2025 Results on Feb 06, 2026EMS-CHEMIE HOLDING AG announced that they will report fiscal year 2025 results on Feb 06, 2026
Board Change • Sep 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Aug 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Chairman of the Board Bernhard Merki was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 15EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025EMS-CHEMIE HOLDING AG, Annual General Meeting, Aug 09, 2025, at 10:30 W. Europe Standard Time.
お知らせ • Jul 13EMS-CHEMIE HOLDING AG announces Annual dividend, payable on August 14, 2025EMS-CHEMIE HOLDING AG announced Annual dividend of CHF 13.9500 per share payable on August 14, 2025, ex-date on August 12, 2025 and record date on August 13, 2025.